Subscribe: MedWorm: Hepatitis C
http://www.medworm.com/rss/medicalfeeds/infectiousdiseases/Hepatitis-C.xml
Added By: Feedage Forager Feedage Grade B rated
Language: English
Tags:
chronic hepatitis  chronic  find christmas  hcv  hepatitis virus  hepatitis  infection  liver  patients  source  treatment  virus 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: MedWorm: Hepatitis C

MedWorm: Hepatitis C



MedWorm.com provides a medical RSS filtering service. Over 7000 RSS medical sources are combined and output via different filters. This feed contains the latest news and research in the Hepatitis C category.



Last Build Date: Tue, 29 Mar 2016 16:32:15 +0100

 



HCV state of the art: Who, when and how to treat

Tue, 29 Mar 2016 09:23:40 +0100

Abstract: Significant progress has been made in treatment of hepatitis C (HCV) infection since the virus was discovered over 26 years ago. After introduction of directly acting agents (DAAs), the treatment for hepatitis C has significantly improved both in efficacy and tolerability. Clinical trials using combinations of DAAs have shown excellent sustained viral response rates (SVRs) in patients with all HCV genotypes. Hepatitis C has now become a curable disease from a chronic disease, and complications such as liver cirrhosis and hepatocellular carcinoma (HCC) are preventable. (Source: International Journal of Infectious Diseases)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Hepatitis C infection in people who inject drugs

Tue, 29 Mar 2016 09:23:40 +0100

Abstract: Hepatitis C virus (HCV) is a major global public health problem. Worldwide, ∼184 million people are infected, with a higher prevalence in developing countries compared to developed countries in North America and Europe. However, vulnerable populations (e.g., people who inject drugs (PWID), Aboriginal people, and incarcerated individuals) account for >80% of new infections and most of the onward transmission. In Bangladesh, PWID account for the vast majority of HCV infections. (Source: International Journal of Infectious Diseases)



Analysis of surveillance data for Hepatitis C in China: From 2005 to 2014

Tue, 29 Mar 2016 09:23:37 +0100

Background: Hepatitis C virus infection represents a significant global public health problem. The disease has been listed as one of the secondary notifiable diseases in China. Early prediction of Hepatitis C is of great importance for heath planning and management. Time series analysis is an effective way to understand the behavior of the epidemic infection. (Source: International Journal of Infectious Diseases)



Prevalence of hepatis C virus infection among asymptomatic Pakistani children

Tue, 29 Mar 2016 09:23:35 +0100

This study was conducted to determine the prevalence of hepatitis C virus (HCV) infection in patients admitted in children ward and attending children outdoor, at Akhtar Saeed hospital, Lahore (a teaching trust hospital). (Source: International Journal of Infectious Diseases)



Indian experience with use of sofusbuvir for treatment of hepatitis C virus infection: Preliminary data from southern India

Tue, 29 Mar 2016 09:23:35 +0100

This study aims to look at the response to sofosbuvir (SOF) (an NS5B nucleotide analog) in combination with RBV with/ without Peg IFN among Indian patients. (Source: International Journal of Infectious Diseases)



Thrombocytopenia and anti-platelet antibodies in patients with chronic hepatitis C

Tue, 29 Mar 2016 09:23:35 +0100

Background: One of the key position in hemostasis belongs to surface platelet receptors (SPR) - glycoproteins (GP) Ia/IIa, Ib/IX and IIb/IIIa. Antibodies to SPR can lead to development of thrombocytopenia in patients with chronic HCV-infection. However the role of different types of antibodies in this process is unknown. (Source: International Journal of Infectious Diseases)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Multiple siRNAs against HCV and host genes are more effective in inhibition of HCV replication

Tue, 29 Mar 2016 09:23:35 +0100

Background: Hepatitis C virus is a major cause of chronic liver diseases such as chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. The present available anti-HCV drugs, Pegylated interferon-α (IFN- α) and Ribavirin have limited efficacy, resistance problems and high manufacturing cost. Among the newer approaches to curb the viral replication, RNA interference (RNAi) based approaches have shown tremendous prospective to inhibit HCV replication. (Source: International Journal of Infectious Diseases)



High prevalence of hepatitis C and hepatitis B infection among pregnant women and their blood donors attending a surgical referral clinic in District Naushahro Feroze, Sindh, Pakistan 2014

Tue, 29 Mar 2016 09:23:35 +0100

Background: Reports on burden of hepatitis C and hepatitis B virus (HCV/HBV) are a big challenge for district to minimize the transmission of associated risk factors. Study was conducted to know the prevalence of HCV/HBV infection in pregnant women and their blood donors attended a surgical referral clinic for cesarean delivery. Study was therefore undertaken to determine the prevalence of HCV/HBV infection among pregnant women and their blood donors. (Source: International Journal of Infectious Diseases)



The efficacy and particular side effects of therapy peginterferon alpha-2a acute hepatitis C hemodialysed patients

Tue, 29 Mar 2016 09:23:35 +0100

Background: Peginterferon alpha-2a is a known standard therapy for patients with acute HCV infection. Our experience with peginterferon in hemodialised patients with hepatitis C started with a million question and uncertainties. This because of the: (Source: International Journal of Infectious Diseases)



Is HLA-DRB1*13 allele a risk factor for prognosis of hepatitis C virus infection?

Tue, 29 Mar 2016 09:23:35 +0100

In this study, we aimed to investigate the effects of HLA-DRB1 alleles on the treatment response and prognosis of the HCV infection. (Source: International Journal of Infectious Diseases)



Correlation of Interferon-gamma and Interleukin-28B levels in patients with chronic hepatitis C viral infection with or without Schistosoma mansoni coinfection

Tue, 29 Mar 2016 09:23:35 +0100

Background: Hepatitis C viral infection (HCV) presents a serious health problem worldwide and is endemic in Egypt. Egypt has the highest prevalence of HCV in the world with an infection rate of one in five individuals. HCV infection in Egypt is usually associated with Schistosoma mansoni coinfection, another endemic disease in Egypt since the Pharos. Interleukin-28B (IL-28B) and interferon-gamma (IFN-g) are two of the mostly recognized immunological cytokines appearing in response to these diseases. (Source: International Journal of Infectious Diseases)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




New treatments for hepatitis C virus (HCV): scope for preventing liver disease and HCV transmission in England

Tue, 29 Mar 2016 09:23:11 +0100

Summary New direct‐acting antivirals have the potential to transform the hepatitis C (HCV) treatment landscape, with rates of sustained viral response in excess of 90%. As these new agents are expensive, an important question is whether to focus on minimizing the consequences of severe liver disease, or reducing transmission via ‘treatment as prevention’. A back‐calculation model was used to estimate the impact of treatment of mild, moderate and compensated cirrhosis on incident cases of HCV‐related end‐stage liver disease/hepatocellular carcinoma (ESLD/HCC). In addition, a dynamic model was used to determine the impact on incidence and prevalence of chronic infection in people who inject drugs (PWID), the main risk group in England. Treating 3500 cirrhotics per year was predic...



Axium Healthcare Pharmacy Launches #oneteam Program – Processes PAs...

Mon, 28 Mar 2016 17:07:02 +0100

#oneteam program ensures providers that all hepatitis C referrals can be sent to Axium(PRWeb March 28, 2016)Read the full story at http://www.prweb.com/releases/2016/03/prweb13292769.htm (Source: PRWeb: Medical Pharmaceuticals)



Factors Influencing Metabolic Parameters in Chronic HCVFactors Influencing Metabolic Parameters in Chronic HCV

Mon, 28 Mar 2016 15:39:15 +0100

What does this new article tell us about the relationship between menopausal status and metabolic abnormalities and the connection to hepatitis C management? Journal of Viral Hepatitis (Source: Medscape Today Headlines)



Treat chronic hepatitis C virus infection in decompensated cirrhosis – pre‐ or post‐liver transplantation? the ironic conundrum in the era of effective and well‐tolerated therapy

Mon, 28 Mar 2016 14:34:09 +0100

Summary The management of hepatitis C virus (HCV) infection in patients with decompensated cirrhosis has evolved dramatically over the past few years mainly due to the availability of all‐oral antiviral regimens. The currently approved all‐oral direct‐acting antivirals (DAA) containing sofosbuvir, ledipasvir, daclatasvir and ribavirin, in various combinations, have shown to be safe and effective in patients with decompensated cirrhosis with sustained virological response (SVR) rates nearly comparable to those with well‐compensated liver disease. Unique issues yet remain such as the challenges with renal insufficiency, tolerability of ribavirin and risk of further hepatic decompensation with a protease inhibitor‐based regimen. While most patients who achieve SVR have demonstrated ...



A Focus on Hepatitis C: OutcomesA Focus on Hepatitis C: Outcomes

Mon, 28 Mar 2016 13:56:31 +0100

Dr William Balistreri completes his three-part series on hepatitis C with a discussion about possible outcomes and a glimpse into the future of treatment. Medscape Gastroenterology (Source: Medscape Today Headlines)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Coinfection of Schistosoma Species with Hepatitis B or Hepatitis C Viruses.

Mon, 28 Mar 2016 10:25:02 +0100

Authors: Abruzzi A, Fried B, Alikhan SB Abstract Although a considerable number of studies have been undertaken to date, it is still controversial as to whether or not coinfection with schistosomiasis increases the susceptibility to or progression from Hepatitis B virus (HBV) or Hepatitis C virus (HCV) infection. This review is a closer examination of the key studies conducted on human populations on clinical factors that were published in English between 1975 and January 2015. Our review is mainly based on tables containing the salient information, which are arranged first by study population, country of study and publication date. We provide further explanation, clarification and discussion in the text. As such, it includes both studies that have been conducted on general populat...



Multiplex electrochemiluminescence DNA sensor for determination of hepatitis B virus and hepatitis C virus based on multicolor quantum dots and Au nanoparticles.

Mon, 28 Mar 2016 04:27:02 +0100

Authors: Liu L, Wang X, Ma Q, Lin Z, Chen S, Li Y, Lu L, Qu H, Su X Abstract In this work, a novel multiplex electrochemiluminescence (ECL) DNA sensor has been developed for determination of hepatitis B virus (HBV) and hepatitis C virus (HCV) based on multicolor CdTe quantum dots (CdTe QDs) and Au nanoparticles (Au NPs). The electrochemically synthesized graphene nanosheets (GNs) were selected as conducting bridge to anchor CdTe QDs551-capture DNAHBV and CdTe QDs607-capture DNAHCV on the glassy carbon electrode (GCE). Then, different concentrations of target DNAHBV and target DNAHCV were introduced to hybrid with complementary CdTe QDs-capture DNA. Au NPs-probe DNAHBV and Au NPs-probe DNAHCV were modified to the above composite film via hybrid with the unreacted complementary CdTe ...



CD44 variant 9 is a potential biomarker of tumor initiating cells predicting survival outcome in hepatitis C virus‐positive patients with resected hepatocellular carcinoma

Sun, 27 Mar 2016 22:00:00 +0100

This study investigated whether the expression of CD44 variant 9 (CD44v9) might be a functional marker of tumor‐initiating stem‐like cells in primary hepatocellular carcinomas (HCCs) of hepatitis C virus (HCV)+ patients and provide an indicator of patient survival, as well as associated mechanisms. A total of 90 HCV+ HCC patients who underwent surgery from 2006 to 2011 were enrolled and monitored for 2–8 years. Expression of CD44v9 was validated immunohistochemically in all HCCs, followed by comparative proteome, survival, and clinicopathological analyses. CD44 variant 8–‐10 was further evaluated in diethylnitrosamine‐induced HCCs of C57Bl/6J mice. Focally localized CD44v+ cells with a membranous staining pattern were detected in human HCV+ and mouse HCCs. CD44v9+ cells of HCCs...



Simeprevir or telaprevir with peginterferon and ribavirin for recurrent hepatitis C after living‐donor liver transplantation: A Japanese multicenter experience

Sat, 26 Mar 2016 23:00:00 +0100

ConclusionSimeprevir‐based triple therapy for recurrent hepatitis C after living‐donor liver transplantation resulted in a high SVR rate and good tolerability, especially in treatment‐naïve patients. (Source: Hepatology Research)



Characterization of partial NS5B region among hepatitis C virus genotype 6 subtypes isolated from thai blood donors

Sat, 26 Mar 2016 23:00:00 +0100

This article is protected by copyright. All rights reserved (Source: Journal of Medical Virology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Preventing Transmission of Zika Virus in Labor and Delivery Settings Through Implementation of Standard Precautions - United States, 2016.

Sat, 26 Mar 2016 14:09:02 +0100

Authors: Olson CK, Iwamoto M, Perkins KM, Polen KN, Hageman J, Meaney-Delman D, Igbinosa II, Khan S, Honein MA, Bell M, Rasmussen SA, Jamieson DJ Abstract Zika virus transmission was detected in the Region of the Americas (Americas) in Brazil in May 2015, and as of March 21, 2016, local mosquito-borne transmission of Zika virus had been reported in 32 countries and territories in the Americas, including Puerto Rico and the U.S. Virgin Islands.* Most persons infected with Zika virus have a mild illness or are asymptomatic. However, increasing evidence supports a link between Zika virus infection during pregnancy and adverse pregnancy and birth outcomes (1), and a possible association between recent Zika virus infection and Guillain-Barré syndrome has been reported (2). Although Zik...



Simeprevir-Sofosbuvir for Chronic Hepatitis C With CirrhosisSimeprevir-Sofosbuvir for Chronic Hepatitis C With Cirrhosis

Fri, 25 Mar 2016 18:30:27 +0100

The combination of simeprevir (SMV) and sofosbuvir (SOF) is effective treatment for patients with chronic hepatitis C virus (HCV) genotype 1 infection and cirrhosis, according to results from OPTIMIST-2. Reuters Health Information (Source: Medscape Gastroenterology Headlines)



Antibiotics Side Effects on the Mitochondria

Fri, 25 Mar 2016 15:38:08 +0100

Science is just beginning to understand how important your mitochondria are to warding off the diseases of aging. And, as usual, mainstream medicine is lagging way behind. Along with your telomeres, the cellular time keepers at the ends of your chromosomes, your mitochondria are another key component of the anti-aging equation. You see, these tiny organelles in your cells are the power plants that turn fuel into energy for your body. Healthy mitochondria keep you young and energetic.  Research shows that damaged mitochondria can lead to: Schizophrenia and bipolar disorder; Alzheimer’s and Parkinson’s disease; Epilepsy, migraines, and nerve pain; Loss of muscle control and balance; Strokes, heart disease, and coronary artery disease; Chronic fatigue syndrome and fibromyalgia;...



Gilead to Pay Merck $200 Million in Damages in Hepatitis C Drug Suit

Fri, 25 Mar 2016 13:43:05 +0100

A federal jury found that Gilead Sciences infringed on two patents held by Merck and its partner Ionis Pharmaceuticals to treat the viral disease. (Source: WSJ.com: Health)



Understanding Zika Virus: An Informational Briefing at the Gladstone Institutes

Fri, 25 Mar 2016 11:15:24 +0100

Gladstone Institutes. 02/11/2016This 48-minute webinar features speakers who explain what is known about Zika virus and how it might be combatted as infections rise across the globe. The speakers are applying their knowledge of hepatitis C and dengue virus, which are related to Zika virus, to study how Zika virus infects cells and leads to disease. They discuss how they hope to identify potential therapeutic targets for Zika. (Video or Multimedia) (Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Hepatitis C Kills More People Than HIV Infection

Fri, 25 Mar 2016 07:00:00 +0100

! (Source: eMedicineHealth.com)



Autoimmune hepatitis: a manifestation of immune reconstitution inflammatory syndrome in HIV infected patients?

Fri, 25 Mar 2016 06:03:02 +0100

Conclusions Immune reconstitution related autoimmune hepatitis should be considered in the differential diagnosis of hepatitis in the HIV-infected patient on antiretroviral therapy. Liver biopsy should be performed and the diagnosis confirmed using scoring systems developed by the Autoimmune Hepatitis Group. Timely treatment with prednisone and other agents for autoimmune hepatitis is indicated, and can be lifesaving in acute liver failure. PMID: 27000683 [PubMed - as supplied by publisher] (Source: Scandinavian Journal of Gastroenterology)



Influence of Host and Viral Factors on Patients with Chronic Hepatitis C Virus Genotype 6 Treated with Pegylated Interferon and Ribavirin: A Systematic Review and Meta-Analysis

Fri, 25 Mar 2016 03:25:02 +0100

Conclusions: Treatment outcomes for HCV-6 patients are superior to those for HCV-1 patients and comparable to those of HCV-2 and HCV-3 patients, especially at 48 weeks. The level of fibrosis affects treatment outcome, but SVR rates are not significantly different between genders. IL28B and IFNL4 polymorphisms are not significantly associated with HCV-6 treatment outcome.Intervirology 2015;58:373-381 (Source: Intervirology)



Business Briefing: Gilead Ordered to Pay Merck $200 Million in Patent Dispute

Fri, 25 Mar 2016 02:22:05 +0100

A federal jury on Thursday ordered Gilead Sciences to pay for infringing two Merck patents related to a lucrative cure for hepatitis C. (Source: NYT Health)



Gilead ordered to pay Merck $200 million in hepatitis C drug patent dispute

Fri, 25 Mar 2016 02:01:35 +0100

SAN JOSE, Calif.,/NEW YORK (Reuters) - A federal jury on Thursday ordered Gilead Sciences Inc to pay Merck & Co $200 million in damages for infringing two Merck patents related to a lucrative cure for hepatitis C. (Source: Reuters: Health)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Atorvastatin and fluvastatin are associated with dose‐dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES

Thu, 24 Mar 2016 23:00:00 +0100

Conclusion: In patients with chronic HCV, statin use was associated with a dose‐dependent reduction in incident cirrhosis and HCC. Atorvastatin and fluvastatin were associated with the most significant antifibrotic effects, compared with other statins. (Hepatology 2016) (Source: Hepatology)



Performance of the New Aptima HCV Quant Dx Assay in Comparison to the Cobas TaqMan HCV2 Test for Use with the High Pure System in Detection and Quantification of Hepatitis C Virus RNA in Plasma or Serum [Virology]

Thu, 24 Mar 2016 23:00:00 +0100

Quantitating the level of hepatitis C virus (HCV) RNA is the standard of care for monitoring HCV-infected patients during treatment. The performances of commercially available assays differ for precision, limit of detection, and limit of quantitation (LOQ). Here, we compare the performance of the Hologic Aptima HCV Quant Dx assay (Aptima) to that of the Roche Cobas TaqMan HCV test, version 2.0, using the High Pure system (HPS/CTM), considered a reference assay since it has been used in trials defining clinical decision points in patient care. The assays' performance characteristics were assessed using HCV RNA reference panels and plasma/serum from chronically HCV-infected patients. The agreement between the assays for the 3 reference panels was good, with a difference in quantitation value...



Viruses, Vol. 8, Pages 91: Frequency of Natural Resistance within NS5a Replication Complex Domain in Hepatitis C Genotypes 1a, 1b: Possible Implication of Subtype-Specific Resistance Selection in Multiple Direct Acting Antivirals Drugs Combination Treatment

Thu, 24 Mar 2016 23:00:00 +0100

In conclusion, the pattern of subtype-specific resistance selection in the naturally occurring strains may guide the treatment option in association with direct acting antivirals (DAAs) targeting different regions, particularly in patients that are difficult to cure, such as those with advanced liver disease or individuals who have failed previous DAAs. (Source: Viruses)



Hepatitis C Disease Burden in the United States in the Era of Oral Direct‐Acting Antivirals

Thu, 24 Mar 2016 23:00:00 +0100

Conclusions: HCV‐associated disease burden will still remain substantial in the era of oral DAAs. Increasing HCV screening and treatment capacity is essential to further decreasing HCV burden in the United States. This article is protected by copyright. All rights reserved. (Source: Hepatology)



Determinants of liver disease progression in children with chronic hepatitis C virus infection.

Thu, 24 Mar 2016 12:58:02 +0100

Authors: Pokorska-Śpiewak M, Kowalik-Mikołajewska B, Aniszewska M, Pluta M, Walewska-Zielecka B, Marczyńska M Abstract Histopathological features and determinants of liver disease progression were analyzed in 42 treatment-naïve children (mean age: 10.7 ±3.7) with chronic hepatitis C (14/42 infected vertically and 26/42 horizontally). Histopathological evaluation was performed according to Knodell's modified system. Predictors of necroinflammation and fibrosis were identified using linear regression analyses. Most children presented with mild necroinflammation and fibrosis (mean grade 4.3 ±2.7, mean staging 1.2 ±0.8), irrespective of the mode of transmission. Vertically infected children were younger than those infected horizontally (8.6 ±2.5 vs. 11.5 ±3.7 years, p = 0.02)....

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




All‐oral daclatasvir plus asunaprevir for chronic HCV genotype 1b infection: a sub‐analysis in Asian patients from the HALLMARK DUAL study

Wed, 23 Mar 2016 23:00:00 +0100

ConclusionsAll‐oral dual therapy with DCV+ASV resulted in high SVR rates and was well‐tolerated in Asian patients with HCV GT‐1b infection.This article is protected by copyright. All rights reserved. (Source: Liver International)



Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvir‐based regimens: results from ERCHIVES

Wed, 23 Mar 2016 23:00:00 +0100

ConclusionsSofosbuvir‐based treatment regimens are highly effective in achieving SVR12. This efficacy is not significantly affected when treated persons receive less than a full prescribed course of treatment. (Source: Liver International)



No Time for Bullies in Hepatitis C Virus Therapy: Genotype 3 Conquered?

Wed, 23 Mar 2016 23:00:00 +0100

Nelson DR, Cooper JN, Lalezari JP, et al; ALLY-3 Study Team. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015;61:1127–1135. (Source: Gastroenterology)



Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients

Wed, 23 Mar 2016 23:00:00 +0100

Interferon-free hepatitis C treatment regimens are effective but very costly. The cost-effectiveness, budget, and public health impacts of current Medicaid treatment policies restricting treatment to patients with advanced disease remain unknown. (Source: Value in Health)



Tuberculosis: The Extremely Rare Case of Narendra

Wed, 23 Mar 2016 20:36:56 +0100

Field newsTuberculosis: The Extremely Rare Case of Narendra March 23, 2016 Since 2006, Doctors Without Borders/Médecins Sans Frontières (MSF) has been providing ambulatory medical and psychosocial care for people in Mumbai living with drug-resistant tuberculosis (DRTB), HIV, hepatitis C, or a combination of these diseases. The majority of the patients are HIV positive who require second or third line treatment. Narendra* is one of only two percent of drug-resistant TB patients in need that have access to these new drugs. (Source: MSF News)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




5 Steps to Deal With a Chronic Illness

Wed, 23 Mar 2016 20:18:59 +0100

I was diagnosed with chronic hepatitis C in 1985, when it was still called non-A non-B. My doctor didn't sugar coat his words when he said to me: "Toni, I am sorry but there is no cure. You have a ticking time bomb inside and nobody can predict how long you have to live." My heart stopped and the course of my life was forever altered. For the next few years, I desperately tried every alternative medicine treatments and modalities to no avail. This virus is a formidable foe. It replicates itself at the speed of light and attacks healthy liver cells leading to fibrosis, cirrhosis and liver cancer. It is the leading cause of liver transplants and has surpassed HIV in yearly fatalities. My most challenging symptom however, was not physical. I felt that my life force was threatened and that th...



Mathematical model may improve hepatitis C drug treatment

Wed, 23 Mar 2016 14:42:47 +0100

Stephen FellerMAYWOOD, Ill., March 23 (UPI) -- Hepatitis C patients are often cured before completing a treatment regimen, suggesting patients require less of the drugs needed to fight the disease. (Source: Health News - UPI.com)



[Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Patients with Decompensated Cirrhosis].

Wed, 23 Mar 2016 02:44:03 +0100

Authors: Gwak GY Abstract HCV-related decompensated liver cirrhosis is a life-threatening illness with an average 5-year survival rate of 50%. Because these patients have higher risk of morbidity and mortality including development of hepatocellular carcinoma, the benefits of eradicating the virus may be greater than in those with less-advanced disease. Recently, direct-acting antiviral agents (DAAs) are replacing interferon-based regimens that have serious adverse events and low tolerability in the treatment of HCV infection. Many clinical trials using combination of several DAAs with or without ribavirin are now actively on-going in HCV-related decompensated cirrhosis, and encouraging data are beginning to appear. In this review, recent advances in the treatment of HCV-related de...



[Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Chronic Hepatitis C Genotype 2 and 3].

Wed, 23 Mar 2016 02:44:03 +0100

Authors: Jung YK Abstract Ever since direct-acting antiviral agents (DAA) have been approved and released into the world, numerous studies on the efficacy, adverse effects and drug-drug interactions of interferon-free DAA combination therapy have been studied and published. With all oral DAA therapy showing sustained virological response rate of 80-90% with minimal adverse events, HCV eradication has now become a realistic goal. DAA combination treatments were approved and adapted to practice in Korea in 2015, and Korean Association for the Study of the Liver (KASL) has revised the guideline based on the systematic approach that reflects evidence-based medicine and expert opinions. In this article, new recommendations for treatment of chronic HCV genotype 2 and 3 infected patients ...

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




[Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Chronic Hepatitis C Genotype 1].

Wed, 23 Mar 2016 02:44:03 +0100

Authors: Park SH Abstract The introduction of direct-acting antiviral agents (DAAs) has markedly improved the sustained virological response (SVR) rates in patients with chronic hepatitis C. Currently, four classes of DAAs targeting three HCV proteins (NS3, NS5A, and NS5B) have been approved for treatment in many countries. Since drugs show advantages and disadvantages, use of a combination of two or more DAAs with different targets or addition of ribavirin in a difficult-to-treat patient shows an SVR rate of ~90% after 12 weeks of treatment or expanded treatment for 24 weeks. Various types of DAA are awaiting approval which will improve the treatment of chronic hepatitis C virus genotype 1 infection. However, high costs, drug resistance and interactions between various drugs remai...



[Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Indications for Treatment].

Wed, 23 Mar 2016 02:44:03 +0100

Authors: Kim KA Abstract The landscape of treatment for HCV infection has evolved substantially with the advent of highly effective direct-acting antiviral agents (DAA). The Korean Association for the Study of the Liver updated guideline for managemnt of hepatitis C in accordance with the introduction of DAA into practice in late 2015. Due to high effectiveness and few side effects of DAA, indications for treatment has been widened to include patients who had been contraindicated for the combination treatment of peginterferon-α and ribavirin, i.e. decompensated cirrhosis and pre- and post-liver transplant setting. As succeesul treatment of HCV can reduce complications of cirrhosis, development of hepatocelluar carcinoma and liver-related mortality, and improve extrahepatic manifes...



Merck Gets Win Over Gilead in Hepatitis C Drug Patent Dispute

Wed, 23 Mar 2016 02:05:25 +0100

Merck won a legal victory over rival Gilead Sciences when a California jury upheld the validity of two patents that Merck says should entitle it to a portion of the multibillion-dollar sales of Gilead’s hepatitis C drugs. (Source: WSJ.com: Health)



Merck Wins Hepatitis C Drug Patent Claim Against Gilead

Wed, 23 Mar 2016 01:03:50 +0100

A jury upheld the validity of Merck patents in a dispute with Gilead Sciences, which could be forced to hand over a portion of the billions of dollars it has made on hepatitis C drugs. (Source: NYT Health)



Merck patents on Hepatitis C treatment found valid in Gilead dispute

Wed, 23 Mar 2016 00:52:28 +0100

SAN JOSE (Reuters) - Merck & Co told a federal jury on Tuesday it was seeking more than $2 billion in damages from rival Gilead Sciences Inc after the jury upheld the validity of two Merck patents in a high-profile dispute over Gilead's blockbuster cure for hepatitis C. (Source: Reuters: Health)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Apolipoprotein E allele frequencies in chronic and self‐limited hepatitis C suggest a protective effect of APOE4 in the course of hepatitis C virus infection

Tue, 22 Mar 2016 23:00:00 +0100

ConclusionsOur findings suggest that the APOE4 allele may confer a protective effect in the course of HCV infection. (Source: Liver International)



Resistance-associated mutations to HCV protease inhibitors naturally pre-existed in HIV/HCV coinfected, treatment-naïve patients

Tue, 22 Mar 2016 23:00:00 +0100

Conclusions The most predominant HCV genotype was 1b in patients with HIV/HCV coinfection. Naturally occurring mutations resistant to HCV PIs (simeprevir, vaniprevir, boceprevir, telaprevir, asunaprevir and paritaprevir) pre-existed in patients with HIV/HCV genotype 1b coinfection. The effects of baseline PI resistance on treatment outcome should be further analyzed. (Source: Clinics and Research in Hepatology and Gastroenterology)



HCV‐induced miR146a controls SOCS1/STAT3 and cytokine expression in monocytes to promote regulatory T‐cell development

Tue, 22 Mar 2016 23:00:00 +0100

Summary Host innate and adaptive immune responses must be tightly regulated by an intricate balance between positive and negative signals to ensure their appropriate onset and termination while fighting pathogens and avoiding autoimmunity; persistent pathogens may usurp these regulatory machineries to dampen host immune responses for their persistence in vivo. Here, we demonstrate that miR146a is up‐regulated in monocytes from hepatitis C virus (HCV)‐infected individuals compared to control subjects. Interestingly, miR146a expression in monocytes without HCV infection increased, whereas its level in monocytes with HCV infection decreased, following Toll‐like receptor (TLR) stimulation. This miR146a induction by HCV infection and differential response to TLR stimulation were recapitul...



Access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study: a person‐centred approach

Tue, 22 Mar 2016 23:00:00 +0100

Summary Socio‐demographic and behavioural characteristics are associated with delayed diagnosis and disease progression in HCV‐infected persons. However, many analyses focused on single variables rather than groups defined by several variables. We used latent class analysis to study all 4488 persons enrolled in the Swiss Hepatitis C Cohort Study. Groups were identified using predefined variables at enrolment. The number of groups was selected using the Bayesian information criterion. Mortality, loss to follow‐up, cirrhosis, treatment status and response to antivirals were analysed using Laplace and logistic regressions. We identified five groups and named them according to their characteristics: persons who inject drugs, male drinkers, Swiss employees, foreign employees and retirees....



A Focus on Hepatitis C: Novel Therapeutic RegimensA Focus on Hepatitis C: Novel Therapeutic Regimens

Tue, 22 Mar 2016 21:48:21 +0100

In the second part of this three-part series, Dr William Balistreri continues his discussion of hepatitis C with a review of new antiviral agents and novel therapeutic strategies. Medscape Gastroenterology (Source: Medscape Pharmacist Headlines)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




The Origin of New-Onset Diabetes After Liver Transplantation: Liver, Islets, or Gut?

Tue, 22 Mar 2016 16:43:21 +0100

Abstract: New-onset diabetes is a frequent complication after solid organ transplantation. Although a number of common factors are associated with the disease, including recipient age, body mass index, hepatitis C infection, and use of immunosuppressive drugs, new-onset diabetes after liver transplantation (NODALT) has the following unique aspects and thus needs to be considered its own entity. First, a liver graft becomes the patient's primary metabolic regulator after liver transplantation, but this would not be the case for kidney or other grafts. The metabolic states, as well as the genetics of the graft, play crucial roles in the development of NODALT. Second, dysfunction of the islets of Langerhans is common in cirrhotic patients and would be exacerbated by immunosuppressive agents, ...



[Comment] A hepatitis-free future: strategy first, then pricing

Tue, 22 Mar 2016 08:07:51 +0100

The Viral Hepatitis Prevention Board met in London, UK (June 5–6, 2015), to discuss options towards a future free of viral hepatitis. Hepatitis B vaccine was introduced in 1982 and is now included in childhood immunisation programmes in 194 countries,1 with substantial declines in incidence rates; hepatitis B virus-dependent hepatitis D prevalence rates have also plummeted. A hepatitis A vaccine is widely used, and a hepatitis E vaccine has become commercially available in China. Chronic hepatitis B treatment exists, and hepatitis C treatment has single-dose oral medicines that can cure up to 95% of cases with shortened treatment and fewer side-effects. (Source: The Lancet Infectious Diseases)



[Corrections] Corrections

Tue, 22 Mar 2016 08:07:51 +0100

Reddy KR, Zeuzem S, Zoulim F, et al. Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial. Lancet Infect Dis 2015; 15: 27–35—The online appendix of this Article has been corrected as of March 21, 2016. (Source: The Lancet Infectious Diseases)



Direct costs of interferon‐based and interferon‐free direct‐acting antiviral regimens for the treatment of chronic hepatitis C infection

Tue, 22 Mar 2016 08:07:11 +0100

Summary Given the increasing budget impact of Hepatitis C virus (HCV) treatment, robust real‐world cost data are essential for healthcare decision‐makers to evaluate and understand the costs and benefits of these treatments. To determine the direct cost of treating HCV infection in a hospital‐based ambulatory care setting in Ireland based on available data from the Irish national hepatitis C treatment registry. A microcosting study of the direct costs of patients with hepatitis C treated with interferon‐based and interferon‐free direct‐acting antiviral regimens was conducted. Attendance at the outpatient clinic for clinical assessment, the quantity of resources used per patient, the medication prescribed and the identification and timing of staff involvement was measured and co...



More cost-effective cure for hepatitis C may be close

Tue, 22 Mar 2016 04:00:00 +0100

(Loyola University Health System) The cost of treating hepatitis C virus could be cut up to 50 percent if mathematical models are used to predict when patients can safely stop taking direct-acting antiviral medication, according to a new study by researchers at Loyola University Health System and Loyola University Chicago. (Source: EurekAlert! - Cancer)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Health-related quality of life in thrombocytopenic patients with chronic hepatitis C with or without cirrhosis in the ENABLE-1 and ENABLE-2 studies

Tue, 22 Mar 2016 00:00:00 +0100

Despite changes in the treatment paradigm towards non-interferon-based therapies, interferon-based treatments are still used in some geographical regions for treating patients with hepatitis C virus (HCV) infe... (Source: Health and Quality of Life Outcomes)



Safety surveillance in haemophilia and allied disorders

Mon, 21 Mar 2016 23:00:00 +0100

Abstract The introduction of clotting factor concentrates has transformed the lives of persons with inherited bleeding disorders. With the use of prophylactic treatment, it is now possible to prevent bleeding in these individuals. The early concentrates were contaminated with the HIV and hepatitis C viruses (HCV) and resulted in major morbidity and mortality in the recipients. Current products are much safer, especially in terms of infectious agents, but other adverse events such as alloantibodies (inhibitors), allergic reactions and thrombotic risks remain of concern. Approximately 30% of previously untreated patients with severe haemophilia A develop inhibitors, making this the most important issue in haemophilia care today. Recently, it was suggested that one of the most commonly used c...



Is increased hepatitis C virus case‐finding combined with current or 8‐week to 12‐week direct‐acting antiviral therapy cost‐effective in UK prisons? A prevention benefit analysis

Mon, 21 Mar 2016 23:00:00 +0100

Conclusions: Increased HCV testing in UK prisons (such as through opt‐out testing) is borderline cost‐effective compared to status quo voluntary risk‐based testing under a £20,000 willingness to pay with current treatments but likely to be cost‐effective if short‐course IFN‐free DAAs are used and could be highly cost‐effective if PWID treatment rates were increased. (Hepatology 2016) (Source: Hepatology)



Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1‐infected patients without cirrhosis: OPTIMIST‐1, a phase 3, randomized study

Mon, 21 Mar 2016 23:00:00 +0100

Conclusion: Simeprevir+sofosbuvir for 12 weeks is highly effective in the treatment of HCV GT1‐infected patients without cirrhosis, including those with Q80K. (Hepatology 2016) (Source: Hepatology)



Inhibition of hepatitis C virus in mouse models by lipidoid nanoparticle-mediated systemic delivery of siRNA against PRK2

Mon, 21 Mar 2016 23:00:00 +0100

Publication date: Available online 22 March 2016 Source:Nanomedicine: Nanotechnology, Biology and Medicine Author(s): Jae-Su Moon, Seung-Hoon Lee, Song-Hee Han, Eun-Jung Kim, Hee Cho, Wooseong Lee, Mi-Kyung Kim, Tae-Eun Kim, Hyun-Ji Park, Jin-Kyu Rhee, Seong-Jun Kim, Seung-Woo Cho, Seung Hyun Han, Jong-Won Oh Host-targeting antivirals have an advantage over direct-acting antivirals in that they have a high genetic barrier to resistance. Here, we describe in vivo anti-hepatitis C virus (HCV) efficacy of a potent siRNA targeting the protein kinase C-related kinase 2 (PRK2), which phosphorylates HCV NS5B RNA-dependent RNA polymerase and promotes HCV replication. PRK2-silencing reduced the phosphorylated NS5B level and resulted in inhibition of NS5B RdRp activity to decrease HC...

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors

Mon, 21 Mar 2016 23:00:00 +0100

Conclusions. The 3D regimen can be coadministered with morning atazanavir and darunavir regimens. However, evening atazanavir plus ritonavir and lopinavir/ritonavir regimens are not recommended in combination with the 3D regimen. (Source: Clinical Infectious Diseases)



Failure to Test and Identify Perinatally Infected Children Born to Hepatitis C Virus-Infected Women

Mon, 21 Mar 2016 23:00:00 +0100

Conclusions. These findings illustrate that a significant number of women giving birth in Philadelphia test positive for HCV and that most of their at-risk children remain untested. To successfully identify all HCV-infected children and integrate them into HCV-specific care, practices for HCV screening of pregnant women and their children should be improved. (Source: Clinical Infectious Diseases)



Erratum to “Barriers to treatment of hepatitis C in HIV/HCV coinfected adults in Brazil” [Braz. J. Infect. Dis. 14 (3) (2010) 237–241]

Mon, 21 Mar 2016 23:00:00 +0100

Publication date: March–April 2016 Source:The Brazilian Journal of Infectious Diseases, Volume 20, Issue 2 Author(s): Maria Cássia Mendes-Corrêa, L.G. Martins, P.A. Ferreira, S. Tenore, O.H. Leite, A.G. Leite, A.J.W. Cavalcante, M. Shimose, M.H. Silva, D.E. Uip (Source: The Brazilian Journal of Infectious Diseases)



Direct‐acting antiviral drugs for the treatment of hepatitis C

Mon, 21 Mar 2016 23:00:00 +0100

New direct‐acting antiviral drug treatments for hepatitis C are more effective, easier to take and have fewer side‐effects than older treatments. New technology appraisals from NICE have recommended specific combinations of these treatments for different patient groups with hepatitis C, meaning that more patients will now have access to these drugs on the NHS. (Source: Prescriber)



Id: 32: agenesis of gallbladder presenting with obstructive jaundice

Mon, 21 Mar 2016 23:00:00 +0100

Case presentation A 64 years old Female with no past medical or surgical history presented with yellowish discoloration of skin for two days duration associated with vague and non-radiating abdominal pain. Patient also endorses 8 pounds unintentional weight loss over the past 2–3 months. On physical exam; scleral icterus and jaundiced skin were noted. Abdominal exam was non-significant, no rash or discoloration on inspection, abdomen is soft with no tenderness or rebound tenderness, murphy sign is negative, no organomegaly, and bowel sounds are positive upon auscultation. No renal costo-vertebral angle tenderness noted. Laboratory testing was significant for: Alanine Aminotransferase (ALT) 448 U/L; Aspartate Aminotransferase (AST) 330 U/L, Alkaline Phosphatase (ALK) 225, Ga...

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Id: 30: hepatitis b virus reactivation in an inactive carrier of chronic hbv after the initiation of treatment for tiberculosis

Mon, 21 Mar 2016 23:00:00 +0100

Discussion HBV reactivation is diagnosed by an increase HBV DNA in chronic carrier with undetectable viral load or rise HBV DNA ≥10-fold increase in HBV DNA compared with baseline. Reactivation of HBV after starting chemotherapy or immunosuppressive medications is well described. Our case report is the first to describe HBV reactivation after starting Ethambutol, levofloxacin and Capreomycin against multidrug resistant mycobacterium tuberculosis. Most studies reported that RIPE (Rifampin, Isoniazid, Pyrazinamide, and Ethambutol) tuberculosis therapy has shown no risk of HBV reactivation. One of the Multidrug resistant tuberculosis therapy agents which is levofloxacin can cause hepatoxicity but all previous studies did not report HBV reactivation. Capreomycin can cause severe hepato...



Id: 55: fibrillary glomerulonephritis:looks like amyloid but its not!

Mon, 21 Mar 2016 23:00:00 +0100

Discussion A study of 66 cases identified most common histologic patterns as mesangial, membranoproliferative, endocapillary proliferative, crescentic and necrotizing, membranous and diffuse sclerosing in order of likelihood.This case had focal segmental and global glomerulosclerosis that is a rare finding. In the same study immunofluorescence staining was positive for IgG in 100%, C3 in 92% and both kappa and lambda in 84% cases. This case also demonstrated positive staining for IgG, kappa and lambda. The pathognomonic finding is presence of fibrillary deposits in the mesangium and glomerular capillary walls distinct from amyloidosis.The size of fibrils ranges from 8–15 nm in Amyloid and 12–24 nm in FGN. IgG is usually monoclonal in AL Amyloid as compared to polyclon...



Systems biology analysis of hepatitis C virus infection reveals the role of copy number increases in regions of chromosome 1q in hepatocellular carcinoma metabolism

Mon, 21 Mar 2016 21:22:26 +0100

Mol. BioSyst., 2016, Accepted ManuscriptDOI: 10.1039/C5MB00827A, PaperIbrahim E. Elsemman, Adil Mardinoglu, Saeed Shoaie, Taysir H Soliman, Jens NielsenHepatitis C virus (HCV) infection is a worldwide healthcare problem; however, traditional treatment methods have failed to cure all patients, and HCV has developed resistance to new drugs. Systems biology-based...The content of this RSS Feed (c) The Royal Society of Chemistry (Source: RSC - Molecular Biosystems)



EMA to review safety of direct-acting antivirals after reports of hepatitis B reactivation

Mon, 21 Mar 2016 17:05:00 +0100

The European Medicines Agency is to review the safety of direct-acting antivirals used to treat patients with chronic hepatitis C infection. (Source: The Pharmaceutical Journal)



FDA approves expanded use of Roche hepatitis C virus RNA test as aid in diagnosis

Mon, 21 Mar 2016 13:48:04 +0100

Test speeds treatment decisions, contributes to better patient care INDIANAPOLIS, March 21, 2016 -- (Healthcare Sales & Marketing Network) -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received approval from the U.S. Food and Drug A... Diagnostics, FDARoche Group, Roche Diagnostics, hepatitis C, COBAS AmpliPrep (Source: HSMN NewsFeed)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Work Productivity of Chronic HCV PatientsWork Productivity of Chronic HCV Patients

Mon, 21 Mar 2016 13:25:52 +0100

Do certain medication regimens help to improve the lives of chronic hepatitis C patients so that their work productivity substantially improves? Journal of Viral Hepatitis (Source: Medscape Today Headlines)



Chemoselective Intermolecular Hydrogen Bonding In Peptides: An Electronic and Topological Study on the H-Bonding Selectivities in Peptidomimetic HCV Protease Inhibitor Telaprevir

Mon, 21 Mar 2016 00:00:00 +0100

Publication date: Available online 21 March 2016 Source:Computational and Theoretical Chemistry Author(s): Gerald J. Tanoury Chemoselectivity in intermolecular hydrogen bonding in polypeptides is demonstrated via a comprehensive study on the H-bonding characteristics of the peptiomimetic hepatitis C protease inhibitor telaprevir (1) using well-established computational tools. Starting with a QTAIM and NBO analysis of the H-bonding selectivities observed in the crystal structure of 1 and its 4-HBA cocrystal, the analysis was extended to model systems of the amino acid residues of 1 (P1res, P3res, and P4res) complexed with formic acid. The carboxylic acid/amide H-bonding of these models showed consistently stronger H-bonding at the P3 residue. The degree of chemoselectivity was quantifid ...



Functional Immune Anatomy of the Liver—As an Allograft

Mon, 21 Mar 2016 00:00:00 +0100

The liver is an immunoregulatory organ in which a tolerogenic microenvironment mitigates the relative “strength” of local immune responses. Paradoxically, necro‐inflammatory diseases create the need for most liver transplants. Treatment of hepatitis B virus, hepatitis C virus, and acute T cell–mediated rejection have redirected focus on long‐term allograft structural integrity. Understanding of insults should enable decades of morbidity‐free survival after liver replacement because of these tolerogenic properties. Studies of long‐term survivors show low‐grade chronic inflammatory, fibrotic, and microvascular lesions, likely related to some combination of environment insults (i.e. abnormal physiology), donor‐specific antibodies, and T cell–mediated immunity. The resulta...



3-(imidazo[1,2-a:5,4-b′]dipyridin-2-yl)aniline inhibits pestivirus replication by targeting a hot spot drug binding pocket in the RNA-dependent RNA polymerase

Mon, 21 Mar 2016 00:00:00 +0100

Publication date: May 2016 Source:Antiviral Research, Volume 129 Author(s): Simone Musiu, Pieter Leyssen, Mathy Froeyen, Jean-Michel Chezal, Johan Neyts, Jan Paeshuyse The compound 3-(imidazo[1,2-a:5,4-b′]dipyridin-2-yl)aniline (CF02334) was identified as a selective inhibitor of the cytopathic effect (CPE) caused by bovine viral diarrhea virus (BVDV) in a virus-cell-based assay. The EC50-values for inhibition of CPE, viral RNA synthesis and the production of infectious virus progeny were 13.0 ± 0.6 μM, 2.6 ± 0.9 μM and 17.8 ± 0.6 μM, respectively. CF02334 was found to be inactive in the hepatitis C subgenomic replicon system. CF02334-resistant BVDV was obtained and was found to carry the N264D mutation in the viral RNA-dependent RNA polymerase (RdRp). Molecular mo...



Activity-Based and Fraction-Guided Analysis of Phyllanthus urinaria Identifies Loliolide as a Potent Inhibitor of Hepatitis C Virus Entry

Mon, 21 Mar 2016 00:00:00 +0100

Publication date: Available online 21 March 2016 Source:Antiviral Research Author(s): Chueh-Yao Chung, Ching-Hsuan Liu, Thierry Burnouf, Guey-Horng Wang, Shun-Pang Chang, Alagie Jassey, Chen-Jei Tai, Cheng-Jeng Tai, Ching-Jang Huang, Christopher D. Richardson, Ming-Hong Yen, Chun-Ching Lin, Liang-Tzung Lin Without a vaccine, hepatitis C virus (HCV) remains a global medical and socio-economic burden, predisposing about 170 million carriers worldwide to end-stage liver diseases including cirrhosis and hepatocellular carcinoma. Although the recently developed direct-acting antivirals (DAAs) have revolutionized hepatitis C treatment, most of them are unsuitable for monotherapy due to risks of resistance, thus necessitating combination with interferon (IFN)-alpha, ribavirin, or a...

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Inhibition of hepatitis C virus in mouse models by lipidoid nanoparticle-mediated systemic delivery of siRNA against PRK2

Mon, 21 Mar 2016 00:00:00 +0100

Host-targeting antivirals have an advantage over direct-acting antivirals in that they have a high genetic barrier to resistance. Here, we describe in vivo anti-hepatitis C virus (HCV) efficacy of a potent siRNA targeting the protein kinase C-related kinase 2 (PRK2), which phosphorylates HCV NS5B RNA-dependent RNA polymerase and promotes HCV replication. PRK2-silencing reduced the phosphorylated NS5B level and resulted in inhibition of NS5B RdRp activity to decrease HCV genome abundance. Systemic administration of lipidoid nanoparticle-formulated PRK2 siRNA (once every three days for a total of three injections at a dose of 3 mg kg−1) resulted in a 3.72 and 1.96 log10 reduction in serum HCV RNA titer, in mouse subcutaneous and orthotopic xenograft models for HCV replication, respectively...



Population attributable fractions of risk factors for hepatocellular carcinoma in the United States

Mon, 21 Mar 2016 00:00:00 +0100

CONCLUSIONSAmong US Medicare recipients, metabolic disorders contribute more to the burden of HCC than any other risk factor, and the fraction of HCC caused by metabolic disorders has increased in the last decade. Cancer 2016. Published 2016. This article is a U.S. Government work and is in the public domain in the USA. (Source: Cancer)



Drug Abuse, HIV, and HCV in Asian Countries

Mon, 21 Mar 2016 00:00:00 +0100

Abstract Drug abuse and co-occurring infections are associated with significant morbidity and mortality. Asian countries are particularly vulnerable to the deleterious consequences of these risks/problems, as they have some of the highest rates of these diseases. This review describes drug abuse, HIV, and hepatitis C (HCV) in Asian countries. The most commonly used illicit drugs include opioids, amphetamine-type stimulants (ATS), cannabis, and ketamine. Among people who inject drugs, HIV rates range from 6.3 % in China to 19 % in Malaysia, and HCV ranges from 41 % in India and Taiwan to 74 % in Vietnam. In the face of the HIV epidemics, drug policies in these countries are slowly changing from the traditional punitive approach (e.g., incarcerating drug users or requiring regis...



Dose- and Formulation-Dependent Non-Linear Pharmacokinetic Model of Paritaprevir, a Protease Inhibitor for the Treatment of Hepatitis C Virus Infection: Combined Analysis from 12 Phase I Studies

Mon, 21 Mar 2016 00:00:00 +0100

Conclusion The complex pharmacokinetics of paritaprevir were well described by the model, which can be used as a basis for clinical trial dosing and further evaluations in patients with HCV. (Source: Clinical Pharmacokinetics)



Dual therapy with peg-interferon and ribavirin in thalassemia major patients with chronic HCV infection: Is there still an indication?

Mon, 21 Mar 2016 00:00:00 +0100

Iron overload and hepatitis C virus (HCV) infection together can lead to chronic liver damage in thalassemia major (TM) patients. (Source: Digestive and Liver Disease)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




The Impact of Prior Flavivirus Infections on the Development of Type 2 Diabetes Among the Indigenous Australians.

Sun, 20 Mar 2016 23:00:00 +0100

Authors: Sorenson A, Owens L, Caltabiano M, Cadet-James Y, Hall R, Govan B, Clancy P Abstract It is estimated that 5% of Australians over the age of 18 have diabetes, with the number of new cases increasing every year. Type 2 diabetes (T2D) also represents a significant disease burden in the Australian indigenous population, where prevalence is three times greater than that of non-indigenous Australians. Prevalence of T2D has been found to be higher in rural and remote indigenous Australian populations compared with urban indigenous Australian populations. Several studies have also found that body mass index and waist circumference are not appropriate for the prediction of T2D risk in indigenous Australians. Regional and remote areas of Australia are endemic for a variety of mosqui...



Activity-Based and Fraction-Guided Analysis of Phyllanthus urinaria Identifies Loliolide as a Potent Inhibitor of Hepatitis C Virus Entry.

Sun, 20 Mar 2016 23:00:00 +0100

Authors: Chung CY, Liu CH, Burnouf T, Wang GH, Chang SP, Jassey A, Tai CJ, Tai CJ, Huang CJ, Richardson CD, Yen MH, Lin CC, Lin LT Abstract Without a vaccine, hepatitis C virus (HCV) remains a global medical and socio-economic burden, predisposing about 170 million carriers worldwide to end-stage liver diseases including cirrhosis and hepatocellular carcinoma. Although the recently developed direct-acting antivirals (DAAs) have revolutionized hepatitis C treatment, most of them are unsuitable for monotherapy due to risks of resistance, thus necessitating combination with interferon (IFN)-alpha, ribavirin, or additional DAAs. More importantly, the high cost associated with the DAAs restricts their accessibility to most parts of the world. Developing novel cost-effective anti-HCV the...



Seroprevalence of Hepatitis C, Hepatitis B, Cytomegalovirus, and Human Immunodeficiency Viruses in Multitransfused Thalassemic Children in Upper Egypt.

Sun, 20 Mar 2016 21:00:01 +0100

Conclusion. The frequency of TTIs, especially HCV, is considerably high among Egyptian children with thalassemia major. It is therefore important to implement measures to improve blood transfusion screening, such as polymerase chain reaction, in order to reduce TTIs from blood donor units. PMID: 26989417 [PubMed] (Source: Advances in Hematology)



Clinical, demographic, and epidemiologic characteristics of hepatitis B virus-infected patients at a tertiary public hospital in Presidente Prudente, State of São Paulo, Brazil

Sat, 19 Mar 2016 22:34:13 +0100

CONCLUSIONS: Over a 13-year interval, very few individuals infected with HBV were identified, highlighting the barriers for caring for patients with HBV in developing countries. New measures need to be implemented to complement curative practices. (Source: Revista da Sociedade Brasileira de Medicina Tropical)



Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals

Sat, 19 Mar 2016 19:19:04 +0100

This article is protected by copyright. All rights reserved (Source: Journal of Medical Virology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




What's next for hepatitis C virus research?

Sat, 19 Mar 2016 00:00:00 +0100

(Source: Hepatology)



Liver mortality attributable to chronic hepatitis C virus infection in Denmark and Scotland—Using spontaneous resolvers as the benchmark comparator

Sat, 19 Mar 2016 00:00:00 +0100

Conclusions: In Denmark and Scotland, the majority of liver death in the CHC‐diagnosed population can be attributed to CHC—nevertheless, an appreciable fraction cannot, cautioning that liver mortality in this population is a compound problem that can be reduced, but not solved, through antiviral therapy alone. (Hepatology 2016) (Source: Hepatology)



L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions

Sat, 19 Mar 2016 00:00:00 +0100

Conclusions. Deep-sequencing analysis confirmed that NS5B variants L159F and V321A emerged in a subset of patients treated with SOF at virologic failure. These variants had no impact on retreatment outcome with SOF, ribavirin, and pegylated interferon. Baseline L159F in genotype 1 did not affect the treatment outcome with LDV/SOF. (Source: The Journal of Infectious Diseases)



Hepatitis C virus antibodies in high risk juvenile onset systemic lupus erythematosus

Sat, 19 Mar 2016 00:00:00 +0100

Conclusions The observed low frequency of anti-HCV antibodies in high risk JSLE suggests that this virus does not seem to have a relevant role in the pathogenesis of this disease. (Source: Revista Brasileira de Reumatologia)



HIV, Hepatitis C, and Other Sexually Transmitted Infections Among Male Sex Workers in Ho Chi Minh City, Vietnam

Fri, 18 Mar 2016 22:07:32 +0100

Abstract There is little data on the burden of HIV and other infections that affect male sex workers (MSW) in Vietnam. We conducted behavioral and biological sexual health surveys with 300 MSW in Ho Chi Minh City. Generalized estimating equation models were built to assess factors associated with HIV, hepatitis C, and other sexually transmitted infections (STI). Of 300 MSW, 19 (6.3 %) were diagnosed seropositive for HIV, 11 (3.7 %) had hepatitis C, and 26 (8.7 %) had at least one prevalent STI. In a multivariable model, opiate use was significantly associated with HIV infection (aOR 6.46, 95 % CI 1.28–32.7) and hepatitis C (aOR = 19.6, 95 % CI 2.35–163.6). Alcohol dependency was associated with increased odds of hepatitis C (aOR = 4.79, 95 % CI 1.02–22.5) and decr...

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




EMA to Review New Hep C Drugs for Possible Hep B ReactivationEMA to Review New Hep C Drugs for Possible Hep B Reactivation

Fri, 18 Mar 2016 18:17:42 +0100

The review follows cases of hepatitis B reactivation in patients infected with hepatitis B and C who were treated with direct-acting antivirals for hepatitis C. News Alerts (Source: Medscape Gastroenterology Headlines)



Payment rise for infected blood victims

Fri, 18 Mar 2016 18:04:17 +0100

People who contracted hepatitis C through infected blood transfusions in Scotland will get increased financial support, Scottish ministers announce. (Source: BBC News | Health | UK Edition)



Shortened Hep C Combo Passes Real-World TestShortened Hep C Combo Passes Real-World Test

Fri, 18 Mar 2016 16:28:31 +0100

An 8-week regimen of combination ledipasvir and sofosbuvir appears to clear the hepatitis C virus as well as a 12-week schedule, even in patients with very high viral loads, new research shows. Medscape Medical News (Source: Medscape Medical News Headlines)



Evaluation of Viremia Frequencies of a Novel Human Pegivirus by Using Bioinformatic Screening and PCR.

Fri, 18 Mar 2016 15:37:03 +0100

Authors: Bonsall D, Gregory WF, Ip CL, Donfield S, Iles J, Ansari MA, Piazza P, Trebes A, Brown A, Frater J, Pybus OG, Goulder P, Klenerman P, Bowden R, Gomperts ED, Barnes E, Kapoor A, Sharp CP, Simmonds P Abstract Next-generation sequencing has critical applications in virus discovery, diagnostics, and environmental surveillance. We used metagenomic sequence libraries for retrospective screening of plasma samples for the recently discovered human hepegivirus 1 (HHpgV-1). From a cohort of 150 hepatitis C virus (HCV)-positive case-patients, we identified 2 persons with HHpgV-1 viremia and a high frequency of human pegivirus (HPgV) viremia (14%). Detection of HHpgV-1 and HPgV was concordant with parallel PCR-based screening using conserved primers matching groups 1 (HPgV) and 2 (HHP...



Hepatitis C-infected kidneys to be used in transplants in clinical trial

Fri, 18 Mar 2016 14:03:43 +0100

Stephen FellerWASHINGTON, March 18 (UPI) -- Doctors at two universities will start transplanting kidneys this spring from donors with hepatitis C to recipients who do not have the infection. (Source: Health News - UPI.com)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.